SCHEMBL6093145

SCHEMBL6093145

CCOC(=O)C=C1CCCCCC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR2 Q92731 1/20 0.53
HCAR2 Q8TDS4 1/20 0.41
RECQL P46063 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
NPSR1 Q6W5P4 1/20 0.39
HSD17B10 Q99714 5/20 0.39
HPGD P15428 4/20 0.39
MAPK1 P28482 4/20 0.39
ALDH1A1 P00352 6/20 0.37
KDM4E B2RXH2 4/20 0.37
JAK2 O60674 1/20 0.37
JAK1 P23458 1/20 0.37
LMNA P02545 3/20 0.36
HTT P42858 1/20 0.36
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA7 P43166 1/20 0.36
CA9 Q16790 1/20 0.36
CA14 Q9ULX7 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3812522 1.00 ESR2 (0.53) ESR2HCAR2RECQLSMN1; SMN2NPSR1
SCHEMBL25311256 1.00 ESR2 (0.53) ESR2HCAR2RECQLSMN1; SMN2NPSR1
SCHEMBL4687838 1.00 ESR2 (0.53) ESR2HCAR2RECQLSMN1; SMN2NPSR1
SCHEMBL25313837 1.00 ESR2 (0.53) ESR2HCAR2RECQLSMN1; SMN2NPSR1
SCHEMBL905258 0.98 ESR2 (0.54) ESR2HCAR2RECQLSMN1; SMN2NPSR1
SCHEMBL1668850 0.94 ESR2 (0.54) ESR2HCAR2RECQLSMN1; SMN2NPSR1
SCHEMBL2502784 0.90
SCHEMBL3597495 0.84 NPSR1 (0.42) ESR2HCAR2RECQLSMN1; SMN2NPSR1
SCHEMBL3597494 0.84 NPSR1 (0.42) ESR2HCAR2RECQLSMN1; SMN2NPSR1
SCHEMBL30601863 0.83 ESR2 (0.47) ESR2RECQLSMN1; SMN2NPSR1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250205362-A1 LIPID NANOPARTICLES NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) 2025-06-26 US disclosed
EP-4501359-A1 LIPID NANOPARTICLES National University Corporation Hokkaido University (JP) 2025-02-05 EP disclosed
WO-2023188830-A1 LIPID NANOPARTICLES 国立大学法人北海道大学 2023-10-05 WO disclosed
US-9720322-B2 Photoresist composition, compound, and production method thereof JSR CORPORATION (JP) 2017-08-01 US disclosed
US-9720322-B2 Photoresist composition, compound, and production method thereof JSR CORPORATION (JP) 2017-08-01 US disclosed
US-20160370700-A1 PHOTORESIST COMPOSITION, COMPOUND, AND PRODUCTION METHOD THEREOF JSR CORPORATION (JP) 2016-12-22 US disclosed
US-20160370700-A1 PHOTORESIST COMPOSITION, COMPOUND, AND PRODUCTION METHOD THEREOF JSR CORPORATION (JP) 2016-12-22 US disclosed
US-9477149-B2 Photoresist composition, compound, and production method thereof JSR CORPORATION (JP) 2016-10-25 US disclosed
US-9477149-B2 Photoresist composition, compound, and production method thereof JSR CORPORATION (JP) 2016-10-25 US disclosed
US-20150004545-A1 PHOTORESIST COMPOSITION, COMPOUND, AND PRODUCTION METHOD THEREOF JSR CORPORATION (JP) 2015-01-01 US disclosed
US-20150004545-A1 PHOTORESIST COMPOSITION, COMPOUND, AND PRODUCTION METHOD THEREOF JSR CORPORATION (JP) 2015-01-01 US disclosed
WO-2006064286-A1 CATHEPSIN S INHIBITORS MEDIVIR UK LTD (GB) 2006-06-22 WO disclosed
WO-2006064286-A1 CATHEPSIN S INHIBITORS MEDIVIR UK LTD (GB) 2006-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250205362-A1 LIPID NANOPARTICLES ECH1, C1R, SGMS1 ESR2 812/4885HCAR2 807/4885RECQL 1508/4885
US-20160370700-A1 PHOTORESIST COMPOSITION, COMPOUND, AND PRODUCTION METHOD THEREOF RARA, H1-0, NR2E3 ESR2 612/4885HCAR2 184/4885RECQL 2370/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.